145 related articles for article (PubMed ID: 28830293)
1. The NARLAL2 dose escalation trial: dosimetric implications of inter-fractional changes in organs at risk.
Hoffmann L; Knap MM; Khalil AA; Lutz CM; Sloth Møller D
Acta Oncol; 2018 Apr; 57(4):473-479. PubMed ID: 28830293
[TBL] [Abstract][Full Text] [Related]
2. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study.
Møller DS; Nielsen TB; Brink C; Hoffmann L; Lutz CM; Drøgemüller Lund M; Hansen O; Schytte T; Khalil AA; Knap MM; Nyhus CH; Ottosson W; Sibolt P; Borissova S; Josipovic M; Persson G; Appelt AL
Radiother Oncol; 2017 Aug; 124(2):311-317. PubMed ID: 28688525
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
5. Intensity-modulated radiotherapy for locally advanced non-small-cell lung cancer: a dose-escalation planning study.
Lievens Y; Nulens A; Gaber MA; Defraene G; De Wever W; Stroobants S; Van den Heuvel F;
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):306-13. PubMed ID: 20888706
[TBL] [Abstract][Full Text] [Related]
6. Adaptive Dose Escalation using Serial Four-dimensional Positron Emission Tomography/Computed Tomography Scans during Radiotherapy for Locally Advanced Non-small Cell Lung Cancer.
Yap ML; Sun A; Higgins J; Clarke K; Marshall A; Becker N; Le LW; Vines DC; Bezjak A; Bissonnette JP
Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):e199-e205. PubMed ID: 27637725
[TBL] [Abstract][Full Text] [Related]
7. Interfractional dose variations in the stomach and the bowels during breathhold intensity-modulated radiotherapy for pancreatic cancer: Implications for a dose-escalation strategy.
Nakamura A; Shibuya K; Nakamura M; Matsuo Y; Shiinoki T; Nakata M; Mizowaki T; Hiraoka M
Med Phys; 2013 Feb; 40(2):021701. PubMed ID: 23387724
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
Murrell DH; Laba JM; Erickson A; Millman B; Palma DA; Louie AV
Radiat Oncol; 2018 Apr; 13(1):57. PubMed ID: 29606150
[TBL] [Abstract][Full Text] [Related]
9. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
[TBL] [Abstract][Full Text] [Related]
10. Potential for adaptive dose escalation in radiotherapy for patients with locally advanced non-small-cell lung cancer in a low mid income setting.
Agrawal S; Kumar S; Maurya AK
Br J Radiol; 2017 Feb; 90(1070):20140234. PubMed ID: 27897060
[TBL] [Abstract][Full Text] [Related]
11. Predicting personalised and progressive adaptive dose escalation to gross tumour volume using knowledge-based planning models for inoperable advanced-stage non-small cell lung cancer patients treated with volumetric modulated arc therapy.
Tambe NS; Pires IM; Moore C; Wieczorek A; Upadhyay S; Beavis AW
Biomed Phys Eng Express; 2022 Mar; 8(3):. PubMed ID: 35189613
[No Abstract] [Full Text] [Related]
12. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.
van Elmpt W; De Ruysscher D; van der Salm A; Lakeman A; van der Stoep J; Emans D; Damen E; Öllers M; Sonke JJ; Belderbos J
Radiother Oncol; 2012 Jul; 104(1):67-71. PubMed ID: 22483675
[TBL] [Abstract][Full Text] [Related]
13. Inhomogeneous dose escalation increases expected local control for NSCLC patients with lymph node involvement without increased mean lung dose.
Nielsen TB; Hansen O; Schytte T; Brink C
Acta Oncol; 2014 Jan; 53(1):119-25. PubMed ID: 23627917
[TBL] [Abstract][Full Text] [Related]
14. Short-course PET based simultaneous integrated boost for locally advanced cervical cancer.
Arnesen MR; Rekstad BL; Stokke C; Bruheim K; Løndalen AM; Hellebust TP; Malinen E
Radiat Oncol; 2016 Mar; 11():39. PubMed ID: 26968827
[TBL] [Abstract][Full Text] [Related]
15. Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of central and ultra-central lung tumours.
Hoffmann L; Persson GF; Nygård L; Nielsen TB; Borrisova S; Gaard-Petersen F; Josipovic M; Khalil AA; Kjeldsen R; Knap MM; Kristiansen C; Møller DS; Ottosson W; Sand H; Thing R; Pøhl M; Schytte T
Radiother Oncol; 2022 Jun; 171():53-61. PubMed ID: 35421513
[TBL] [Abstract][Full Text] [Related]
16. A planning study of radiotherapy dose escalation of PET-active tumour volumes in non-small cell lung cancer patients.
Møller DS; Khalil AA; Knap MM; Muren LP; Hoffmann L
Acta Oncol; 2011 Aug; 50(6):883-8. PubMed ID: 21767188
[TBL] [Abstract][Full Text] [Related]
17. Computational delineation and quantitative heterogeneity analysis of lung tumor on 18F-FDG PET for radiation dose-escalation.
Wang X; Cui H; Gong G; Fu Z; Zhou J; Gu J; Yin Y; Feng D
Sci Rep; 2018 Jul; 8(1):10649. PubMed ID: 30006600
[TBL] [Abstract][Full Text] [Related]
18. Intensity modulated arc therapy implementation in a three phase adaptive (18)F-FDG-PET voxel intensity-based planning strategy for head-and-neck cancer.
Berwouts D; Olteanu LA; Speleers B; Duprez F; Madani I; Vercauteren T; De Neve W; De Gersem W
Radiat Oncol; 2016 Apr; 11():52. PubMed ID: 27039294
[TBL] [Abstract][Full Text] [Related]
19. Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer.
Roelofs E; Engelsman M; Rasch C; Persoon L; Qamhiyeh S; de Ruysscher D; Verhaegen F; Pijls-Johannesma M; Lambin P;
J Thorac Oncol; 2012 Jan; 7(1):165-76. PubMed ID: 22071782
[TBL] [Abstract][Full Text] [Related]
20. Individualized dose prescription for hypofractionation in advanced non-small-cell lung cancer radiotherapy: an in silico trial.
Hoffmann AL; Troost EG; Huizenga H; Kaanders JH; Bussink J
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1596-602. PubMed ID: 22245206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
